BCL2L1 and neoplasm: Comparable increases in transgenic BCLX protein expression were not observed in splenocytes from premalignant Eμ‐MYC/Vav‐BCLX DT vs. premalignant Vav‐BCLX TG mice, although levels increased mildly in Eμ‐MYC/Vav‐BCLX tumours (Fig. 7D).